• Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals

    13 days ago - By Xconomy

    Seattle Genetics is in line to receive $1.72 billion from Merck via a pair of deals , one for a cancer drug that's still in development and the other for partial rights to a therapy that won FDA approval earlier this year. The larger of the two deals is for the drug still in clinical development, ladiratuzumab vedotin. According to terns announced Monday, the two companies have agreed to jointly develop that drug, both by itself and in combination with Merck blockbuster cancer drug pembrolizumab. The deal calls for Merck to pay Bothell, WA-based SeaGen (NASDAQ: SGE...
    Read more ...